Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interleukin-6 and C-reactive protein prognostic value following acute coronary syndrome.

European heart journal·2026
Same author

Post-transcriptional modifications on tRNA fragments confer functional changes to high-density lipoproteins in atherosclerosis.

Atherosclerosis·2025
Same author

Oxidized Phospholipids, Lipoprotein(a), and Cardiovascular Outcomes After Acute Coronary Syndrome.

Circulation·2025
Same author

Author Correction: Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis.

Nature medicine·2025
Same author

Multiplex Apolipoprotein Panel Improves Cardiovascular Event Prediction and Cardiovascular Outcome by Identifying Patients Who Benefit From Targeted PCSK9 Inhibitor Therapy.

Arteriosclerosis, thrombosis, and vascular biology·2025
Same author

Impact of PREVENT Cardiovascular Risk Equations on Statin Eligibility by Subgroup and Risk Thresholds: A Cross-Sectional Study.

Journal of general internal medicine·2025
Same journal

An integrative approach to patient selection for mitral transcatheter edge-to-edge repair in secondary mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Rebooting blood vessel repair: implications of the SEMA-VR CardioLink-15 trial.

Current opinion in cardiology·2026
Same journal

Advancements in wearable technology for heart failure patients.

Current opinion in cardiology·2026
Same journal

Minimally invasive approaches to coronary artery bypass grafting: techniques, current evidence, and future directions.

Current opinion in cardiology·2026
Same journal

Advances in artificial intelligence for the evaluation of mitral regurgitation.

Current opinion in cardiology·2026
Same journal

Role of nutritional interventions to reduce cardiometabolic disease burden in the community.

Current opinion in cardiology·2026
See all related articles

Related Experiment Video

Updated: Jun 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Are statins diabetogenic?

Uchechukwu K Sampson1, Macrae F Linton, Sergio Fazio

  • 1Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee 37232-6300, USA. u.sampson@vanderbilt.edu

Current Opinion in Cardiology
|April 19, 2011
PubMed
Summary
This summary is machine-generated.

Statins, used to lower cholesterol and prevent heart disease, may modestly increase the risk of developing new-onset diabetes. Regular glucose monitoring is recommended for patients on statin therapy.

Related Experiment Videos

Last Updated: Jun 2, 2026

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
09:15

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Area of Science:

  • Cardiovascular Medicine
  • Endocrinology
  • Pharmacology

Background:

  • Statins are primary agents for low-density lipoprotein (LDL) cholesterol reduction and atherosclerotic cardiovascular disease (ASCVD) prevention.
  • While generally safe, recent attention focuses on an increased risk of incident diabetes with long-term statin use.

Purpose of the Study:

  • To review clinical trial evidence linking statin therapy to incident diabetes.
  • To explore potential biological mechanisms underlying this association.

Main Methods:

  • Review of clinical trial evidence, including placebo-controlled and standard care-controlled trials.
  • Analysis of meta-analyses reporting on statin use and incident diabetes.
  • Examination of experimental evidence for proposed mechanisms.

Main Results:

  • Large clinical trials and meta-analyses indicate a modest increase in the risk of incident diabetes with statin therapy (9-13% increased risk).
  • Mechanisms may involve inhibition of beta-cell glucose transporters, altered ATP production, pro-inflammatory effects, impaired insulin secretion, and beta-cell apoptosis.

Conclusions:

  • Clinical trial data support a modest increase in incident diabetes risk with statins.
  • This presents a therapeutic paradox, as statins are crucial for cardiovascular risk reduction in diabetic patients.
  • Regular glucose monitoring is advised for individuals taking statins.